---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-197717"
form_type: "8-K"
ticker: null
cik: "0001305253"
company_name: "Eiger BioPharmaceuticals, Inc."
filed_at: "2023-07-28T23:59:59+00:00"
generated_at: "2026-06-12T22:53:04.971390+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eiger BioPharmaceuticals receives Nasdaq bid price deficiency notice; 180 days to regain compliance

## Summary
- Nasdaq notified Eiger that bid price closed below $1.00 for 30 consecutive business days as of July 26, 2023.
- Eiger has 180 calendar days, until Jan 22, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant by deadline, Eiger may be eligible for another 180-day period if it meets other listing standards.
- Eiger may consider a reverse stock split to cure the deficiency.
- No immediate effect on listing; stock continues trading under symbol EIGR.

## SEC filing metadata
- accession: 0001193125-23-197717
- form_type: 8-K
- cik: 0001305253
- company_name: Eiger BioPharmaceuticals, Inc.
- filed_at: 2023-07-28T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1305253/000119312523197717/0001193125-23-197717-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1305253/000119312523197717/d518845d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-197717
- JSON: https://secwatch.observer/filing/0001193125-23-197717.json
- Plain text: https://secwatch.observer/filing/0001193125-23-197717.txt

## Key facts
- Listing & Compliance Notices
  Eiger BioPharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A)
  source text: July 26, 2023, Eiger BioPharmaceuticals, Inc. (“Eiger”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying Eiger that, for the last 30 consecutive business days, the bid price for Eiger’s common stock, par value $0.001 per share (the “Common Stock”), closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Pe
  evidence_url: https://www.sec.gov/Archives/edgar/data/1305253/000119312523197717/0001193125-23-197717-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.